BRPI0403290A - Prognósticos para câncer de mama - Google Patents

Prognósticos para câncer de mama

Info

Publication number
BRPI0403290A
BRPI0403290A BR0403290-0A BRPI0403290A BRPI0403290A BR PI0403290 A BRPI0403290 A BR PI0403290A BR PI0403290 A BRPI0403290 A BR PI0403290A BR PI0403290 A BRPI0403290 A BR PI0403290A
Authority
BR
Brazil
Prior art keywords
breast cancer
tips
microarrays
genes
analyzing
Prior art date
Application number
BR0403290-0A
Other languages
English (en)
Inventor
Yixin Wang
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BRPI0403290A publication Critical patent/BRPI0403290A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

"PROGNóSTICOS PARA CâNCER DE MAMA". é conduzido um processo para fornecer um prognóstico de câncer de mama pela análise da expressão de um grupo de genes. Os perfis de expressão de gene em uma variedade de meio tais como microarranjos estão incluídos assim como os kits que contêm os mesmos.
BR0403290-0A 2003-04-24 2004-04-26 Prognósticos para câncer de mama BRPI0403290A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/422,522 US7306910B2 (en) 2003-04-24 2003-04-24 Breast cancer prognostics

Publications (1)

Publication Number Publication Date
BRPI0403290A true BRPI0403290A (pt) 2005-07-12

Family

ID=32962443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0403290-0A BRPI0403290A (pt) 2003-04-24 2004-04-26 Prognósticos para câncer de mama

Country Status (10)

Country Link
US (2) US7306910B2 (pt)
EP (1) EP1471154A3 (pt)
JP (1) JP2004344171A (pt)
KR (1) KR20040096423A (pt)
CN (1) CN1715421A (pt)
AR (1) AR044099A1 (pt)
AU (2) AU2004201706A1 (pt)
BR (1) BRPI0403290A (pt)
CA (1) CA2462747A1 (pt)
MX (1) MXPA04003931A (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
CN101965190A (zh) * 2005-04-04 2011-02-02 维里德克斯有限责任公司 乳腺肿瘤的激光显微解剖和微阵列分析揭示雌激素受体相关的基因和途径
EP1983046A4 (en) * 2006-02-03 2009-03-25 Messengerscape Co Ltd GENERAL GROUP APPLICABLE TO CANCER PROSTICE
CA2674907C (en) 2007-01-31 2017-04-04 Celera Corporation A molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof
US20100255470A1 (en) * 2007-04-05 2010-10-07 Source Percision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Breast Cancer
JP2011520183A (ja) * 2008-04-25 2011-07-14 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ サンプルデータの分類
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US8597885B2 (en) * 2009-01-28 2013-12-03 University Of Notre Dame Accelerated progression relapse test
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
KR101421326B1 (ko) * 2010-03-30 2014-07-21 서울대학교산학협력단 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
CN104662166A (zh) * 2012-04-20 2015-05-27 纪念斯隆-凯特琳癌症中心 与转移性乳腺癌相关的基因表达图谱
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
CN110172461B (zh) * 2019-06-03 2023-05-09 上海长征医院 一种新型骨肉瘤肺转移模型的构建方法及其应用
CN119185542B (zh) * 2024-08-20 2025-04-01 中国人民解放军总医院京南医疗区 Armc7抑制剂在制备用于治疗黑色素瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500010A (ja) 1997-12-23 2002-01-08 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物ｉ
WO2002010436A2 (en) 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
WO2002059271A2 (en) 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
PT1410011E (pt) * 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
WO2004079014A2 (en) 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer

Also Published As

Publication number Publication date
US20040214179A1 (en) 2004-10-28
US8183353B2 (en) 2012-05-22
AU2004201706A1 (en) 2004-11-11
CA2462747A1 (en) 2004-10-24
EP1471154A2 (en) 2004-10-27
US20100009861A1 (en) 2010-01-14
MXPA04003931A (es) 2004-11-29
AR044099A1 (es) 2005-08-24
EP1471154A3 (en) 2005-02-09
KR20040096423A (ko) 2004-11-16
AU2004201761A1 (en) 2004-11-11
US7306910B2 (en) 2007-12-11
CN1715421A (zh) 2006-01-04
JP2004344171A (ja) 2004-12-09

Similar Documents

Publication Publication Date Title
BRPI0603053A (pt) previsão de reicidiva de osso de cáncer de mama
BRPI0518734A2 (pt) prognàstico de cÂncer de pulmço
BRPI0403169A (pt) Prognósticos de câncer colorretal
WO2005083429A3 (en) Breast cancer prognostics
ATE398138T1 (de) Neues verfahren für die diagnose und prognose von malignen erkrankungen
WO2018005811A8 (en) Differential tagging of rna for preparation of a cell-free dna/rna sequencing library
CN106282165A (zh) 一种植物内生菌16S rRNA基因扩增方法及应用
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
Northcott et al. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years
EP2514826A3 (en) Use of interfering RNA molecules to down regulate the expression of specific genes or family of genes
AR044099A1 (es) Pronostico de cancer de mama
WO2008048193A3 (en) Breast tumour grading
AU2015308620A8 (en) Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
EP2333112A3 (en) Breast cancer prognostics
MX389717B (es) COMPOSICIONES Y MÉTODOS PARA CONSTRUIR GENOTECAS DE ADNc ESPECÍFICAS DE HEBRA.
BR0303012A (pt) Avaliação de câncer colorretal
ATE532868T1 (de) Apoptose induzierende positivkontrolle für expressionsmodulationsexperimente
BR0303091A (pt) Avaliação de câncer colorretal
BR0303092A (pt) Portfólio para prognóstico de câncer de mama
BRPI0403812A (pt) Prognósticos de câncer coloretal
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
BRPI0608429A2 (pt) método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido
Tang et al. Detection of microRNAs in prostate cancer cells by microRNA array
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.